Thus, we observed decreased glycolysis in the tumor cells treated with API-2 or everolimus, in line with recent reports in other human cancer cells, as well as with the connection between AKT/mTOR/p70S6K signaling in cancer and glycolysis [29, 30, 41]. The gene discussed is RPS6KB1; the disease is neoplasm.